Jul. 30, 2013, 5:15 PM
- With the deal for Optimer (OPTR), Cubist (CBST) gets the antibacterial drug Dificid, which it has co-promoted with OPTR since 2011. CEO Michael Bonney notes that the co-promotion experience combined with CBST's "outstanding hospital-based commercial infrastructure," should allow for the maximization of the drug's potential.
- Previously, some worried disappointing Q1 Dificid sales ($16.8M versus estimates of ~$20M) would make OPTR less attractive as a takeout target.
- In the Trius (TSRX) deal, CBST gets the antibiotic tedizolid phosphate (developed with Bayer outside the U.S.), a phase IV treatment for Gram-positive infections.
Jul. 30, 2013, 4:54 PM
Jul. 30, 2013, 10:43 AM
- Merck (MRK -0.2%) CEO Ken Frazier says it plans to "aggressively manage" costs, while supporting key brands and drug research projects.
- The company doesn't rule out shedding its animal-health and consumer-care businesses, with Frazier saying that if the asset proves to be more productive outside the company, it would consider the alternatives.
- New research chief Roger Perlmutter says the company's going to be applying more stringent controls over the direction its R&D takes, stressing the move is necessary to strengthen investment returns.
- Perlmutter also says he will "fully participate" in drug-licensing activity.
- Listen to the Webcast here: Merck Earnings Call
Jul. 30, 2013, 7:58 AM
- Merck's (MRK) worldwide revenue falls 11% Y/Y as Singulair sales dip 80% from Q2 2012 — the asthma treatment lost patent expiration in the U.S. last August and in Europe in February.
- Overall, Q2 pharmaceutical sales fall 12% to $9.3B.
- Revenue growth (including FX impact) from other key products: Januvia, 1%; Zetia, 3%; Remicade, 2%; Junumet, 16%; Vytorin, -6%; Isentress, 4%; Gardasil, 18%; Proquad, M-M-R II, Varivax, 7%; Nasonex, 11%; Consumer Care, -11% (impact of terminating distribution arrangements in China).
- Outlook: FY $3.45-3.55/ share; revenue -5 to -6% Y/Y. Shares -0.19% premarket. (PR)
Jul. 30, 2013, 7:03 AM
- Merck (MRK): Q2 EPS of $0.84 beats by $0.01.
- Revenue of $11.0B misses by $0.22B. (PR)
Jul. 30, 2013, 12:05 AM
- ACI, ADS, AET, ARQL, AUDC, BLC, BP, BYD, CIE, CMI, COH, CVLT, DB, DDD, DIN, DISCA, DSX, ECL, ESV, ETR, EZPW, FIS, GLW, GNRC, GT, GTI, GTLS, HCP, HEP, HRS, HW, IPGP, JBLU, KLIC, MCGC, MDC, MLM, MRK, MSO, MWV, NEE, NLSN, NOV, NTLS, NYX, ODP, OSK, OXY, PBI, PEG, PES, PFE, ROK, S, SAN, SNH, TRI, TRW, UBS, UDR, VSH, WLK, WM, WU, XYL
Jul. 29, 2013, 5:30 PM
- ACI, ADS, AET, ARQL, AUDC, BLC, BP, BYD, CIE, CMI, COH, CVLT, DB, DDD,DIN, DISCA, DSX, ECL, ESV, ETR, EZPW, FIS, GLW, GNRC, GT, GTI, GTLS, HCP, HEP, HRS, HW, IPGP, JBLU, KLIC, MCGC, MDC, MLM, MRK, MSO, MWV, NEE, NLSN,NOV, NTLS, NYX, ODP, OSK, OXY, PBI, PEG, PES, PFE, ROK, S, SAN,SNH, TRI, TRW, UBS, UDR, VSH, WLK, WM, WU, X, XYL
Jul. 26, 2013, 9:00 AM
The EMA's CHMP finalizes a review of GLP-1-based diabetes therapies and concludes that "presently available data do not confirm recent concerns over an increased risk of pancreatic adverse events with these medicines." Approved GLP-1 based drugs include AstaZeneca (AZN) and Bristol-Myers' (BMY) Bydureon, Novo Nordisk's (NVO) Victoza, Sanofi's (SNY) Lyxumia, Merck's (MRK) Januvia, AZN's Komboglyze, Eli Lilly (LLY) and Boehringer Ingelheim's Jentadueto, and Novartis' (NVS) Galvus.| Jul. 26, 2013, 9:00 AM | 1 Comment
Jul. 24, 2013, 11:51 AM
The FDA accepts Merck's (MRK -0.5%) NDA for the investigational anti-thrombotic medicine, vorapaxar for "the secondary prevention of cardiovascular events in patients with a history of heart attack and no history of stroke or transient ischemic attack." The drug has faced an uphill battle since being acquired by MRK in 2009 and, according to Reuters, some analysts question whether bleeding risk will limit its adoption if approved.| Jul. 24, 2013, 11:51 AM
Jul. 22, 2013, 8:13 AMSix global pharmaceutical companies, including Merck (MRK), Novartis (NVS), Roche (RHHBY.OB) and Sanofi (SNY) could come under scrutiny in China as they have reportedly used a travel agency that's been linked to the GSK corruption scandal. Documents seen by the NYT show that the firms contracted Shanghai Linjiang International Travel Agency to organize events and conferences. However, there's no evidence of wrongdoing. Merck and Roche acknowledge using the agency. | Jul. 22, 2013, 8:13 AM | 1 Comment
Jul. 19, 2013, 12:45 PM
Jul. 19, 2013, 11:04 AM
Merck (MRK +1%) will pay a total of $23M to compensate consumers for Vioxx-related economic losses in the drug maker's latest effort to put litigation surrounding the painkiller in the rear view mirror. Consumers will get a one-time payment of $50 contingent upon proof of prescription and can receive "up to $75 in connection with a post-withdrawal medical consultation."| Jul. 19, 2013, 11:04 AM | 1 Comment
Jul. 18, 2013, 6:38 PMMore on Cubist Pharmaceuticals (CBST): Q2 comes in mixed, missing on the bottom line but beating on top line revenue. Net earnings fell 65% as the biopharmaceutical company was hit by higher costs that more than offset 12% Y/Y revenue growth. U.S. Cubicin sales jumped 14% to $227.1M, while Entereg sales climbed 28% to $12.4M. R&D expenses also surged however, rising 71% to $115.2M. Shares +1.2% AH. | Jul. 18, 2013, 6:38 PM
Jul. 18, 2013, 4:22 PM
Cubist Pharmaceuticals (CBST) says it's initiating Phase 3 efficacy studies of bevenopran in patients with chronic non-cancer pain and opioid-induced constipation. The program includes three identically-designed studies that will enroll approximately 600 patients each designed to evaluate the drug's efficacy and safety, and includes a 1,400-patient one-year, placebo-controlled safety study which was initiated in October 2012.| Jul. 18, 2013, 4:22 PM
Jul. 18, 2013, 4:04 PMCubist Pharma (CBST): Q2 EPS of $0.42 misses by $0.13. Revenue of $258.8M beats by $3.87M. (PR) | Jul. 18, 2013, 4:04 PM
Jul. 18, 2013, 12:10 AM